J. Goldman & CO LP Zymeworks Inc. Transaction History

J. Goldman & CO LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$4.65 - $7.43 $1.2 Million - $1.92 Million	258,298 Added 789.85%	291,000 $1.79 Million
Q2 2022 Aug 15, 2022	BUY	$4.82 - $7.7 $157,623 - $251,805	32,702 New	32,702 $173,000
Q4 2021 Feb 14, 2022	SELL	$15.19 - $29.33 $759,378 - $1.47 Million	-49,992 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$27.35 - $37.28 $491,479 - $669,921	-17,970 Reduced 26.44%	49,992 $1.45 Million
Q2 2021 Aug 16, 2021	BUY	$26.5 - $38.23 $1.8 Million - $2.6 Million	67,962 New	67,962 $2.36 Million
Q4 2018 Feb 14, 2019	SELL	$10.95 - $15.44 $550,598 - $776,369	-50,283 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$12.21 - $16.61 $1.28 Million - $1.74 Million	-104,967 Reduced 67.61%	50,283 $789,000
Q2 2018 Aug 14, 2018	BUY	$11.13 - $21.86 $1.73 Million - $3.39 Million	155,250 New	155,250 $2.3 Million

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $901M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.